Advertisement
Research Article

Novel Chikungunya Vaccine Candidate with an IRES-Based Attenuation and Host Range Alteration Mechanism

  • Kenneth Plante,

    Affiliation: Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America

    X
  • Eryu Wang,

    Affiliation: Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America

    X
  • Charalambos D. Partidos,

    Affiliation: Inviragen Inc, Madison, Wisconsin and Fort Collins, Colorado, United States of America

    X
  • James Weger,

    Affiliations: Inviragen Inc, Madison, Wisconsin and Fort Collins, Colorado, United States of America, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, United States of America

    X
  • Rodion Gorchakov,

    Affiliation: Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America

    X
  • Konstantin Tsetsarkin,

    Affiliation: Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America

    X
  • Erin M. Borland,

    Affiliation: Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America

    X
  • Ann M. Powers,

    Affiliation: Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America

    X
  • Robert Seymour,

    Affiliation: Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America

    X
  • Dan T. Stinchcomb,

    Affiliation: Inviragen Inc, Madison, Wisconsin and Fort Collins, Colorado, United States of America

    X
  • Jorge E. Osorio,

    Affiliation: Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, United States of America

    X
  • Ilya Frolov,

    Affiliation: Department of Microbiology, University of Alabama, Birmingham, Alabama, United States of America

    X
  • Scott C. Weaver mail

    sweaver@utmb.edu

    Affiliation: Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America

    X
  • Published: July 28, 2011
  • DOI: 10.1371/journal.ppat.1002142

About the Authors

Kenneth Plante, Eryu Wang, Rodion Gorchakov, Konstantin Tsetsarkin, Robert Seymour, Scott C. Weaver
Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
Charalambos D. Partidos, James Weger, Dan T. Stinchcomb
Inviragen Inc, Madison, Wisconsin and Fort Collins, Colorado, United States of America
James Weger, Jorge E. Osorio
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, United States of America
Erin M. Borland, Ann M. Powers
Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America
Ilya Frolov
Department of Microbiology, University of Alabama, Birmingham, Alabama, United States of America

Corresponding Author

Email: sweaver@utmb.edu

Competing Interests

CDP, JW and DTS are employees of Inviragen, Inc. DTS is a stockholder and board member of Inviragen, Inc. JEO is a consultant and stockholder of Inviragen, Inc. IF and SCW are inventors on a UTMB patent application describing IRES-attenuated alphavirus vaccines. Inviragen has obtained license to the patent for commercial development.

Author Contributions

Conceived and designed the experiments: KP EW CDP RS DS JO IF SCW. Performed the experiments: KP EW CDP RG KT EMB AMP RS JW. Analyzed the data: KP EW CDP RG KT EMB AMP RS. Wrote the paper: KP RS SCW.